---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-024136"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:46:21.549103+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Femasys Q1 2023 net loss $2.95M; Health Canada approves FemaSeed & FemCerv

## Summary
- Net loss of $2,946,257 ($0.25 basic & diluted EPS) vs $2,883,030 ($0.24) YoY.
- Revenue $293,984, down 8.5% YoY; U.S. sales up 11.6%, international sales nil.
- Raised $3.9M in registered direct offering closed April 20, 2023; cash runway into Q2 2024.
- Health Canada approved FemaSeed (infertility) and FemCerv (cervical sampler) in April/May 2023.
- Cash and equivalents $10.2M as of March 31, 2023.

## SEC filing metadata
- accession: 0001140361-23-024136
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036123024136/0001140361-23-024136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036123024136/brhc20052828_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-024136
- JSON: https://secwatch.observer/filing/0001140361-23-024136.json
- Plain text: https://secwatch.observer/filing/0001140361-23-024136.txt

## Key facts
- Earnings Releases
  FEMASYS INC reported the first quarter ended March 31, 2023 results: revenue $293,984, net income $2,946,257, EPS $0.25 per basic and diluted share.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $293,984
  - Net income: $2,946,257
  - EPS: $0.25 per basic and diluted share
  - Result: reported results
  source text: in facility and other overhead costs mainly for directors & officers (D&O) insurance, and a decrease in legal and certain professional costs. • Sales decreased by $27,421 to $293,984 for the three months ended March 31, 2023, from $321,405 for the same period last year. U.S. sales, however, increased by $30,624, or 11.6%, for the three months ended March 31,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036123024136/0001140361-23-024136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.